Surface Oncology to Appoint Robert Ross, M.D., as President and Chief Executive Officer
11 févr. 2021 07h00 HE
|
Surface Oncology, Inc.
Experienced clinical development executive to succeed current CEO Jeff Goater, who will become Chairman of the Board Transition effective April 1, 2021 CAMBRIDGE, Mass., Feb. 11, 2021 (GLOBE...
Surface Oncology to Participate in H.C. Wainwright Bioconnect 2021 Conference
11 janv. 2021 06h00 HE
|
Surface Oncology, Inc.
CAMBRIDGE, Mass., Jan. 11, 2021 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor...
Surface Oncology Announces Exclusive License Agreement with GSK for Novel Immunotherapy Program
17 déc. 2020 06h55 HE
|
Surface Oncology, Inc.
GSK will have exclusive rights to develop and commercialize SRF813, a novel antibody targeting PVRIG Surface Oncology to receive $85 million upfront payment CAMBRIDGE, Mass., Dec. 17, 2020 (GLOBE...
Surface Oncology to Participate in the 3rd Annual Evercore ISI HealthCONx Conference
25 nov. 2020 07h00 HE
|
Surface Oncology, Inc.
CAMBRIDGE, Mass., Nov. 25, 2020 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor...
Surface Oncology Announces SRF617 and SRF388 Will Advance to Combination and Expansion Stages of Ongoing Phase 1 Clinical Trials
13 nov. 2020 07h05 HE
|
Surface Oncology, Inc.
Both programs have successfully escalated to dose levels demonstrating pharmacodynamic activity without dose-limiting toxicities Detailed clinical data for each program to be presented at a medical...
Surface Oncology Announces FDA Fast Track Designation Granted by U.S. Food and Drug Administration for SRF388 to Treat Liver Cancer
11 nov. 2020 07h00 HE
|
Surface Oncology, Inc.
CAMBRIDGE, Mass., Nov. 11, 2020 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor...
Surface Oncology Reports Financial Results and Corporate Highlights for Third Quarter 2020
10 nov. 2020 06h20 HE
|
Surface Oncology, Inc.
CAMBRIDGE, Mass., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor...
Surface Oncology to Present at the Cowen IO Next Summit
09 nov. 2020 16h25 HE
|
Surface Oncology, Inc.
CAMBRIDGE, Mass, Nov. 09, 2020 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor...
Surface Oncology to Present SRF388 and SRF114 Preclinical Data at the Upcoming Society for Immunotherapy for Cancer 2020 Virtual Conference
09 nov. 2020 09h00 HE
|
Surface Oncology, Inc.
SRF388 inhibits hepatocellular carcinoma tumor growth as a single agent in a preclinical model SRF114 induces destruction of tumor Tregs through antibody-dependent cellular cytotoxicity CAMBRIDGE,...
Surface Oncology to Report SRF388 Preclinical Data at the Upcoming International Cytokine and Interferon Society’s Cytokines 2020 Virtual Conference
26 oct. 2020 16h05 HE
|
Surface Oncology, Inc.
CAMBRIDGE, Mass., Oct. 26, 2020 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor...